超声引导泡沫硬化治疗促进静脉性腿部溃疡愈合的疗效
本多中心随机对照试验将静脉性腿部溃疡患者随机分为两组:A组在标准治疗基础上接受超声引导泡沫硬化治疗(UGFS)处理远端反流静脉网,B组仅接受标准治疗。A组溃疡完全愈合时间显著短于B组(中位35天 vs 56天,P=0.008),3个月内完全愈合率更高(97% vs 75%,P=0.01)。结论认为UGFS是标准治疗的有价值辅助手段。
要点
- A组溃疡完全愈合时间中位35天,显著短于B组的56天(P=0.008)。
- A组3个月内完全愈合率为97%(28/29),高于B组的75%(27/36)(P=0.01)。
- 多因素回归显示UGFS对愈合时间有显著影响(P=0.004),A组溃疡面积缩小更快(P<0.0001)。
核心结论
- 两组均从标准治疗中获益,但加用UGFS显著改善治疗结局,加速愈合过程,缩短完全愈合时间并提高3个月内完全愈合率。
- 作者认为UGFS是静脉性腿部溃疡的有价值辅助治疗,可增强标准治疗方案的疗效。
研究设计与样本
- 多中心随机对照试验(ISRCTN18090073),共招募71例患者(其中6例为双侧溃疡),剔除脱落和失访后65个溃疡纳入分析。
- A组接受UGFS处理远端反流静脉网(如溃疡床静脉丛)加标准治疗,B组仅接受标准治疗;标准治疗包括压力治疗、伤口护理、浅静脉反流消融及适当时近端深静脉梗阻再通。
- 患者每周随访直至溃疡完全愈合,所有参与者自随机化起随访至少12个月,以计算研究期间总无溃疡天数并评估溃疡愈合后复发情况及生活质量。
- 主要结局为溃疡愈合时间;次要结局包括溃疡愈合率、静脉临床严重程度评分和患者报告的健康相关生活质量。
- 研究在半数患者完成随访的计划中期分析时因疗效显著而提前终止。
主要发现
- A组溃疡完全愈合时间中位35天(四分位距22天),B组中位56天(四分位距58天),A组显著短于B组(P=0.008)。
- 3个月内完全愈合:A组28/29(97%),B组27/36(75%),A组高于B组(P=0.01)。
- 多因素回归分析显示UGFS对愈合时间有显著影响(P=0.004)。
- A组溃疡面积缩小速度显著快于B组(P<0.0001)。
- A组和B组治疗后静脉临床严重程度评分均显著改善(P<0.0001)。
临床怎么用
- 原文结论认为UGFS是静脉性腿部溃疡的有价值辅助治疗,可增强标准治疗方案的疗效。
局限性
- 研究因疗效显著而在计划中期分析时提前终止。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultrasound-guided foam sclerotherapy (UGFS) for treating the refluxing venous network beneath and in the vicinity of venous leg ulcers (VLUs) has been used widely. OBJECTIVE: This trial aimed to assess the efficacy and safety of UGFS for treating VLUs (ISRCTN18090073). METHODS: This study is a multicenter randomized controlled trial. Consenting eligible participants were randomized into two groups: group A received UGFS for the distal refluxing network of veins (eg, ulcer bed venous plexus), in addition to standard care, and group B received standard care alone. Standard care included compression therapy, wound care, ablation of superficial reflux, and recanalization of proximal deep venous obstruction when appropriate. Patients were followed weekly until complete ulcer healing was achieved. All participants will be followed for ≥12 months from the point of randomization to allow calculation of total ulcer-free days during the study period and assess for the recurrence of ulceration from the time of ulcer healing and quality of life measures. The primary outcome was the time to ulcer healing. Secondary outcomes were the rate of ulcer healing, Venous Clinical Severity Score, and patient-reported health-related quality of life. RESULTS: The study was terminated early for efficacy at the planned interim analysis when one-half the number of patients had completed follow-up. A total of 71 patients, 6 with bilateral VLUs, were recruited. After accounting for dropouts and losses to follow-up, 65 VLUs were available for analysis. Both groups were similar at baseline regarding demographic factors, risk factors, history of deep vein thrombosis, previous venous interventions, and ulcer size. The time to complete ulcer healing was significantly shorter in group A, who received UGFS, as compared with group B, who did not receive UGFS (median, 35 days [interquartile range, 22 days] vs median, 56 days [interquartile range, 58 days]; P = .008). Additionally, more ulcers achieved complete healing within 3 months in group A compared with group B (28/29 [97%] vs 27/36 [75%]; P = .01). Multivariate regression analysis showed a significant effect of UGFS on healing time (P = .004). Group A showed a significantly more rapid reduction in ulcer size (P < .0001). There was a significant improvement in the Venous Clinical Severity Score after treatment in both groups A and B (P < .0001). CONCLUSIONS: Although both groups benefited from standard care for treating VLUs, the addition of UGFS improved treatment outcomes significantly. UGFS accelerated the healing process, resulting in a shorter time to complete ulcer healing and a higher rate of ulcers achieving complete healing within 3 months. These findings suggest that UGFS is a valuable adjunctive treatment for VLUs, enhancing the efficacy of standard care protocols.
引用
- Bishara RA, Gaweesh A, Hanna IN, et al. Efficacy of ultrasound-guided foam sclerotherapy in the healing of venous leg ulcers. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40209875. doi:10.1016/j.jvsv.2025.102244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。